Latest Breaking News On - Priority medicines - Page 1 : comparemela.com

Hansa Biopharma AB: Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

Hansa Biopharma AB: Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomPrnewswire hansa biopharmaHansa biopharmaStephanie kenneyEvan ballantyneEuropean medicines agencyInternational phaseVp global corporate affairsEuropean unionDrug administrationBiologic license applicationGlomerular filtration rateChief financialPriority medicinesHuman leukocyte antigensProduct characteristics

Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomHansa biopharmaStephanie kenneyEvan ballantynePrnewswire hansa biopharmaEuropean unionEuropean medicines agencyVp global corporate affairsDrug administrationInternational phaseBiologic license applicationGlomerular filtration rateChief financialPriority medicinesHuman leukocyte antigensProduct characteristics

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew jerseyUnited statesBryan dunnMandy faheyJames chalmersEleanor barisserMartina flammerEsteve pharmaceuticalsPrnewswire insmed incorporated nasdaqCompany annual report on formCorporate communicationsSchool of medicineInsmed incorporatedExchange commissionDrug administration

Insmed Incorporated: Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

-Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus

United kingdomNew jerseyUnited statesMartina flammerEleanor barisserJames chalmersMandy faheyBryan dunnEsteve pharmaceuticalsPrnewswire insmed incorporated nasdaqCompany annual report on formCorporate communicationsSchool of medicineInsmed incorporatedExchange commissionDrug administration

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at EASL International Liver Congress

89bio, Inc. announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis with fibrosis.

Drug administrationEuropean associationBreakthrough therapyPriority medicinesEuropean medicines agenda